Find Drugs Regulator Latest News, Videos & Pictures on Drugs Regulator and see latest updates, news, information from NDTV.COM. Explore more on Drugs Regulator.

Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...

Photo: mike blake/Reuters Eli Lilly LLY 0.62% agreed to acquire Verve Therapeutics VERV -0.27% for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio.

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health drugs.

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and more than $650 million in milestones.

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Visa, Netflix and Eli Lilly are moving closer to the trillion dollar club. While all three have the potential, one will reach $3 trillion sooner than the others.

We came across a bullish thesis on Eli Lilly and Company (LLY) on Business Model Mastery’s Substack. In this article, we will summarize the bulls’ thesis on LLY.

Pharma Rx Rundown: Merck, Sanofi, Eli Lilly and more Check out this week’s medical marketing news, dealmaking and industry chatter. Heerea Rikhraj June 5, 2025 4:17 pm ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain medicine.